UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 167

Sortiert nach

Hydroxychloroquine Destabilizes Phospho-S6 in Human Renal Carcinoma Cells

PloS one, 2015-07, Vol.10 (7), p.e0131464-e0131464

2015

Volltextzugriff (PDF)

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

Journal of clinical oncology, 2012-04, Vol.30 (12), p.1371-1377

2012

Volltextzugriff (PDF)

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

The lancet oncology, 2007-11, Vol.8 (11), p.975-984

2007

Volltextzugriff (PDF)

Sunitinib in patients with metastatic renal cell carcinoma

JAMA : the journal of the American Medical Association, 2006-06, Vol.295 (21), p.2516

2006

Volltextzugriff (PDF)

Targeting mTOR in renal cell carcinoma

Cancer, 2009-05, Vol.115 (S10), p.2313-2320

Hudes, Gary R.

2009

Volltextzugriff (PDF)

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2006-01, Vol.24 (1), p.16-24

2006

Volltextzugriff (PDF)

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Journal of clinical oncology, 2004-03, Vol.22 (5), p.909-918

2004

Volltextzugriff (PDF)

Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2009-09, Vol.27 (27), p.4462-4468

2009

Volltextzugriff (PDF)

Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma

Journal of clinical oncology, 2012-10, Vol.30 (28), p.3545-3551

2012

Volltextzugriff (PDF)

Sunitinib Efficacy Against Advanced Renal Cell Carcinoma

The Journal of urology, 2007-11, Vol.178 (5), p.1883-1887

2007

Volltextzugriff (PDF)

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical cancer research, 2009-12, Vol.15 (23), p.7421-7428

2009

Volltextzugriff (PDF)

PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection

Cancer immunology research, 2014-04, Vol.2 (4), p.320-331

2014

Volltextzugriff (PDF)

Serum Amino Acid Levels as a Biomarker for Renal Cell Carcinoma

The Journal of urology, 2011-10, Vol.186 (4), p.1206-1212

2011

Volltextzugriff (PDF)

Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus

Journal of clinical oncology, 2011-05, Vol.29 (13), p.1750-1756

2011

Volltextzugriff (PDF)

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma

Cancer chemotherapy and pharmacology, 2014-10, Vol.74 (4), p.739-750

2014

Volltextzugriff (PDF)

Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma

Journal of clinical oncology, 2007-09, Vol.25 (25), p.3958-3964

2007

Volltextzugriff (PDF)

Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer

Journal of clinical oncology, 2009-01, Vol.27 (1), p.100-105

2009

Volltextzugriff (PDF)

Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer

Clinical cancer research, 2014-04, Vol.20 (7), p.1925-1934

2014

Volltextzugriff (PDF)

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma

Cancer chemotherapy and pharmacology, 2014, Vol.73 (1), p.151-161

2014

Volltextzugriff (PDF)

A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

Cancer, 2014-06, Vol.120 (11), p.1647-1655

2014

Volltextzugriff (PDF)

Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma

Seminars in oncology, 2009-12, Vol.36, p.S26-S36

2009

Volltextzugriff (PDF)

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium: A trial of the eastern cooperative oncology group

Cancer, 2004-04, Vol.100 (8), p.1639-1645

2004

Volltextzugriff (PDF)

Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805)

American journal of clinical oncology, 2019-04, Vol.42 (4), p.375

2019

Volltextzugriff (PDF)

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

Journal of clinical oncology, 1999-11, Vol.17 (11), p.3461-3467

1999

Volltextzugriff (PDF)

1 – 25 von 167

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(165)
Mit Volltextzugriff
(137)

Publikationsform

Artikel
(166)
magazinearticle
(1)

Sprache

Englisch
(166)
Japanisch
(14)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Hydroxychloroquine Destabilizes Phospho-S6 in Human Renal Carcinoma Cells

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

Sunitinib in patients with metastatic renal cell carcinoma

Targeting mTOR in renal cell carcinoma

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma

Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma

Sunitinib Efficacy Against Advanced Renal Cell Carcinoma

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection

Serum Amino Acid Levels as a Biomarker for Renal Cell Carcinoma

Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma

Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma

Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer

Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma

A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium: A trial of the eastern cooperative oncology group

Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805)

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

Suchergebnisse filtern